Evidence map›Paper›PMID 41778234›Full record

ReviewCancer diagnosis & prognosis

Fadi G Haddad, Elias J Jabbour, Stephen W Gutkin, Ashutosh K Pathak, Yifan Zhai, Hagop M Kantarjian

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fadi G HaddadDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.
Elias J JabbourDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.
Stephen W GutkinDepartment of Medical Affairs, Ascentage Pharma Group Inc., Rockville, MD, U.S.A.
Ashutosh K PathakDepartment of Medical Affairs, Ascentage Pharma Group Inc., Rockville, MD, U.S.A.
Yifan ZhaiChief Medical Officer, Ascentage Pharma Group Inc., Rockville, MD, U.S.A.
Hagop M KantarjianDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aim: Widespread use of BCR::ABL1 tyrosine kinase inhibitors (TKIs) has transformed the clinical landscape of chronic myeloid leukemia (CML). However, Materials and Methods: This is the first chart review of Results: Across most time points, failure and warning signs by molecular testing were not significantly more frequent in patients who did or did not undergo Conclusion: There were few significant differences in failure and warning signs by molecular testing in patients who did or did not undergo mutational profiling. Patients who underwent

Indexed as

BCR::ABL1chronic myeloid leukemiamutationreviewtreatment resistancetyrosine kinase inhibitors

Identifiers

PMID41778234
PMCPMC12951377

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.